Topical rapamycin (sirolimus) for facial angiofibromas
Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at...
Main Author: | Bhushan Madke |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Indian Dermatology Online Journal |
Subjects: | |
Online Access: | http://www.idoj.in/article.asp?issn=2229-5178;year=2013;volume=4;issue=1;spage=54;epage=57;aulast=Madke |
Similar Items
-
Use of topical rapamycin in facial angiofibromas in Indian skin type
by: Vishalakshi Viswanath, et al.
Published: (2016-01-01) -
Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient
by: Resham J Vasani
Published: (2015-01-01) -
Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence
by: Clara Cortell Fuster, et al.
Published: (2022-05-01) -
Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
by: Marie Monaghan, et al.
Published: (2022-08-01) -
Dermoscopy of Facial Angiofibromas in Four Patients of Skin of Color with Tuberous Sclerosis Complex: A Case-Series
by: Rashmi Jindal, et al.
Published: (2021-07-01)